Table 1 Comparison of basic information between case group and control group

Gender, n (%)

0.498

 Male

156 (35)

52 (38)

104 (34)

 Female

286 (65)

85 (62)

201 (66)

Age, n (%)

0.015*

 ≥18~<40

23 (5)

5 (4)

18 (6)

 ≥40~<60

206 (47)

52 (38)

154 (50)

 ≥60

213 (48)

80 (58)

133 (44)

BMI, n (%)

< 0.001***

 <24

294 (67)

108 (79)

186 (61)

 ≥24

148 (33)

29 (21)

119 (39)

Tumor distance from the anal verge, n (%)

0.005**

 ≥5 cm

377 (85)

127 (93)

250 (82)

 <5 cm

65 (15)

10 (7)

55 (18)

Distant metastasis, n (%)

0.613

 No

370 (84)

117 (85)

253 (83)

 Yes

72 (16)

20 (15)

52 (17)

Lymph node, n (%)

0.021*

 No

328 (74)

112 (82)

216 (71)

 Yes

114 (26)

25 (18)

89 (29)

Depth of tumor infiltration, n (%)

0.002**

 I-II

223 (50)

85 (62)

138 (45)

 III-IV

219 (50)

52 (38)

167 (55)

Pathological type, n (%)

0.269

 Adenocarcinoma

420 (95)

132 (96)

288 (94)

 Mucinous adenocarcinoma

15 (3)

2 (1)

13 (4)

 Signet ring cell carcinoma

7 (2)

3 (2)

4 (1)

Neoadjuvant chemotherapy, n (%)

< 0.001***

 No

112 (25)

58 (42)

54 (18)

 Yes

330 (75)

79 (58)

251 (82)

Postoperative chemotherapy, n (%)

< 0.001***

 No

138 (31)

65 (47)

73 (24)

 Yes

304 (69)

72 (53)

232 (76)

Anastomotic leakage, n (%)

0.058

Features

Total (n = 442)

No delayed closure (n = 137)

Delayed closure (n = 305)

p

 No

385 (87)

126 (92)

259 (85)

 Yes

57 (13)

11 (8)

46 (15)

Anastomotic stenosis, n (%)

0.004**

 No

401 (91)

133 (97)

268 (88)

 Yes

41 (9)

4 (3)

37 (12)

LARS, n (%)

0.2

 No

299 (68)

99 (72)

200 (66)

 Yes

143 (32)

38 (28)

105 (34)

Complications, n (%)

1

 No

373 (84)

116 (85)

257 (84)

 Yes

69 (16)

21 (15)

48 16)